AR mRNA expression in these cases is consistent with analyses performed using both BC molecular subtypes and IHC-surrogate subtypes, showing that AR mRNA levels are higher in HER2-enriched tumors compared to basal-like and TNBC tumors, respectively. The gene discussed is ERBB2; the disease is breast cancer.